What Cambridge Technologies does

Cambridge Technologies is a privately held, independent custom vaccine manufacturer founded in 2015 and headquartered at 1525 Bioscience Drive in Worthington, Minnesota. The company specializes in autogenous vaccines — USDA-approved, herd-specific biologics manufactured from the precise viral and bacterial strains isolated from a customer's own animals — and is described by the company itself as the industry leader in autogenous vaccines for U.S. beef and dairy cattle. Its core methodology, branded Precision Vaccinology, couples a full-service Next Generation Diagnostics laboratory using next-generation sequencing to identify all circulating pathogens in submitted samples with Quality Custom Manufacturing to produce bacterial, viral, or combination vaccines tailored to the requesting veterinarian's herd. Adjacent manufacturing brands include SoliDose (a partnered pelleted immediate-release / programmed-release dual-dose system with SolidTech Animal Health), Score (an antigen-expression processing approach), Versa-Dose and Precision Select (customizable adjuvant technologies produced internally rather than sourced from third parties), and the DataBridge cloud-based diagnostic management platform.

The company's product footprint spans four livestock segments: Production Animal Veterinarians in Bovine (primary, where it claims market leadership), Swine (PRRSV, Mycoplasma and other respiratory and enteric pathogens), Small Ruminant (an emerging segment for Campylobacter, Caseous Lymphadenitis, and footrot), and Poultry (entered in 2025 through a strategic partnership with Merck Animal Health, including an experimental Avian Metapneumovirus Type A and Type B combination autogenous vaccine). Its go-to-market is sales-led and B2B: dedicated Account Managers take custom orders directly from veterinarians, forecast usage, manage customer inventory, and serve as the ongoing relationship contact. For poultry, Cambridge leverages Merck's field and technical expertise and customer network for distribution. The company advertises over 100 million doses delivered, 400+ years of combined animal-health team experience, and quotes-based pricing for custom orders placed under multi-year vet relationships. The company remains privately held and has disclosed a single early financing round of $3.5M in January 2018; founding leadership includes co-founder and President Wayne Freese and co-founder and Chief Strategy Officer Randy Simonson.

Name

Cambridge Technologies

Legal name

Cambridge Technologies

Website

https://cambridgetechnologies.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Cambridge Technologies is a U.S. custom autogenous vaccine manufacturer that uses next-generation diagnostics and proprietary manufacturing (Precision Vaccinology, SoliDose, Score) to produce herd-specific vaccines for production animal veterinarians across bovine, swine, poultry, and small ruminant markets.

Ownership category

akta.pro rank

Product category

Veterinary Biological Products

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Autogenous (Herd-Specific) Vaccines (HLAMAKAF)

akta.pro secondary industries

Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Poultry Vaccines (HLAMAKAC), Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO) (HLAMAKAI), Veterinary Vaccines (Biologics) (HLAMAEAL)

Keywords

• Autogenous animal vaccines
• Custom vaccine manufacturing
• Herd health diagnostics
• Livestock biologics
• Veterinary vaccine production

Headquarters

HQ city

Worthington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Autogenous Vaccines: Cambridge Technologies manufactures custom autogenous vaccines for livestock (bovine, swine, small ruminant, poultry). These are USDA-approved herd-specific vaccines derived from precise strains affecting specific herds. Vaccines can be bacterial, viral, or a combination, and are all custom-made to order.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Cambridge Technologies manufactures USDA-approved autogenous (herd-specific) vaccines for production animals, derived from the precise strains affecting a given herd. Vaccines can be bacterial, viral, or combination, and are custom-made to order for veterinarians serving bovine, swine, small ruminant, and poultry operations. Production is enabled by the company's Precision Vaccinology® platform, which pairs next-generation sequencing diagnostics with custom manufacturing and proprietary adjuvant and delivery technologies.

Product overview

Cambridge Technologies is a custom vaccine company offering Precision Vaccinology® as its core methodology, combining next-generation diagnostics with quality custom manufacturing for autogenous vaccines. The product portfolio includes SoliDose® (pelleted dual-dose vaccines for cattle with IR/PR technology), Score™ (antigen expression optimization), Versa-Dose™ (flexible adjuvant technology for beef systems), and Precision Select™ (customized adjuvant selection for swine). DataBridge provides cloud-based diagnostic management connecting clinics, veterinarians, and lab results. The company serves bovine, swine, poultry, and small ruminant markets with species-specific vaccines and diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• Precision Vaccinology®: The company's proprietary approach combining next-generation diagnostics with quality custom manufacturing for herd-specific vaccines
• SoliDose®
• Score™
• Versa-Dose™
• Precision Select™
• DataBridge

Products and services

• Precision Vaccinology® Core methodology combining Next Generation Diagnostics (NGS-based) with quality custom manufacturing to identify pathogens in herd samples and produce herd-specific autogenous vaccines for veterinarians serving production animals.
• Autogenous Vaccines USDA-approved herd-specific vaccines derived from the precise strains affecting a given herd, custom-manufactured to order as bacterial, viral, or combination products for production animal veterinarians.
• SoliDose® Pelleted dual-dose autogenous biologics for beef and dairy cattle that deliver an Immediate Release dose plus an automatic Programmed Release booster dose (over 2-3 weeks) in a single administration, administered via the SoliDoser device.
• Score™ Advanced antigen expression processing that selects and improves expression of surface and core cross-reactive antigens from gram-positive and gram-negative bacteria, allowing broad recognition by the animal's immune system.
• Versa-Dose™ Versatile adjuvant technology that gives veterinarians flexibility to construct vaccine protocols that meet varied handling challenges across different types of beef production systems.
• Precision Select™ Customized adjuvant technology combining diagnostics, advanced manufacturing, and selective adjuvant selection to deliver on-farm disease solutions; adjuvants are produced internally rather than sourced from third parties.
• DataBridge Cloud-based diagnostic management platform providing secure storage of diagnostic results, paperless database, management tools, and custom reporting to enable proactive herd health management for clinics and veterinarians.
• Avian Metapneumovirus Type A + Type B Combination Autogenous Vaccine Experimental autogenous poultry vaccine combining Avian Metapneumovirus Type A and Type B in a single bottle, distributed through Cambridge Technologies' partnership with Merck Animal Health.

Quantifiable outcome

• Over 100 million autogenous vaccine doses administered to animals nationwide
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• Merck Animal HealthcoreStrategic or Co-development PartnerCambridge Technologies partners with Merck Animal Health to offer autogenous vaccines for poultry. Cambridge contributes production expertise and distribution while Merck provides field and technical expertise as well as customer networking. This partnership enables Cambridge to offer the U.S. poultry industry's first experimental autogenous vaccine to target Avian Metapneumovirus Type A in combination with Type B in one bottle.
• SolidTech Animal HealthcoreStrategic or Co-development PartnerCambridge Technologies and SolidTech Animal Health combine their manufacturing technologies to create pelleted IR/PR herd-specific equivalents using SolidTech's patented SoliDose process. SolidTech provides the proprietary SoliDose technology for pelleted vaccine delivery.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Zoetis: Largest pure-play animal health company globally with a deep livestock vaccine franchise; competes broadly with Cambridge in cattle, swine, and poultry biologics.
• Ceva Animal Health: Global animal health company with vaccines and autogenous capabilities across poultry, swine, and cattle — a broad incumbent that overlaps with Cambridge in target species.
• Phibro Animal Health: Diversified animal health and nutrition company with a meaningful autogenous and livestock vaccine portfolio, competing with Cambridge across the same production animal customers.
• Elanco Animal Health: Major animal health incumbent with a broad livestock vaccine portfolio; competes with Cambridge for cattle, swine, and poultry biologics budgets across the same veterinarian channel.
• Boehringer Ingelheim Animal Health: Major veterinary vaccines player with strong swine and poultry franchises, competing with Cambridge for production animal biologics share.

Direct peers

• Vaxxinova: Specialist in autogenous (herd-specific) vaccines for livestock and poultry, making it the closest direct competitor to Cambridge's core business across species and customization model.
• Benchmark Biolabs: Custom autogenous biologics and diagnostics provider for livestock, overlapping with Cambridge's herd-specific vaccine and diagnostic offering.
• Colorado Serum Company: Veterinary biologics manufacturer producing vaccines and diagnostics for livestock; a comparable independent player in the U.S. veterinary biologics market.
• Hygieia Biological Laboratories: Independent autogenous vaccine manufacturer serving livestock producers with herd-specific biologics, directly comparable to Cambridge's species and customization approach.
• Newport Laboratories (Merck Animal Health): Autogenous vaccine specialist acquired by Merck Animal Health; competes directly with Cambridge in custom biologics and is part of the same Merck distribution ecosystem that partners with Cambridge in poultry.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/cambtech
• Facebookfacebook.com/cambridgetech
• LinkedInlinkedin.com/company/cambridge-technologies-biotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cambridge Technologies